Member Info for Adastra

The company has had a stream of acquisitions since 2012..Healthpoint Bio, Arthrocare, Blue Belt Tech, Brainlab, Atracsys Sark Integra Life sciences, and Engage Surgical spending about $3.3bn. These have been integrated into the three current divisions. A lot of the hard work has been done here to put S&N centre stage in future growth areas. Covid and Ukraine have given the Company significant hurdles to overcome in line with the other US based orthopaedics manufacturers. Nath certainly eluded to these and his reassurance was absent...terrible just terrible for a new CEO. Had he reinforced the fact that the backlog of operations requiring company products was snowballing daily and that the new Malaysian facility is already helping ease logistics then it would have thrown out a vision of competency in the face of adversity. We need a can-do rather than a can't-be-arsed-to leader here. It's glaringly òbvious to all but the Muppets who installed him. The Company is solid with over a century of provenance, unbroken divis and an unequalled reputation among surgeons and medical practitioners. It is breaking new ground on robotic surgery and AI and is the globes second largest supplier of medical dressings. I hope today has hit the nadir where intrinsic value is evident despite the Muppet at the helm. So many potential players must be card counting at present.

Someone somewhere is sitting on a huge BUY button........and we must be getting close.....
Let the bidding begin.......

Well said I42....hopefully we are near a level where its been driven low enough to realise that the technology itself is unaffected by the CEO and he can be eliminated by consolidation.

And, heaven forbid, were Changzou Meditech or Suzhou Sunan to 'acquire' substantial Capital investment and launch a bid........ Boom....

Anyone who thinks that unlikely does not understand the appetite of American financiers and investors who will spot the compelling reasons for this kind of action.

One hint of interest at this opportunistic time would start a major bidding war imo. All the Medtronic orthopaedic companies must be watching as they'll need to gauge their response in advance. This specialist healthcare sector has huge barriers to entry with provenance and reputation being paramount....Smith & Nephew has both in impressive amounts and consolidation is pretty much the only way a competitor can grow. Sat in the crosshairs!

Stryker and Zimmer MUST also be looking at S&N... would be insane not to given the economies of scale and US tax breaks on the acquisition. Adding the IP and specialities with 2 new SOTA facilities in UK and Malaysia gives easy expansion to address the enormous backlog of operations worldwide. Private Equity will also be doing the math but an existing titan either in this or allied field would be my bet. All the BoD at Smith and Nephew have done by appointing Nath is to erect an up for grabs sign to predators.

Just such a shame that J&J are in the process of restructuring their organisation in the same way GSK split otherwise this is a screaming fit into their operations and would be earnings enhancing very quickly with their slick management and economies of assimilation into existing ops. Bet their BoD is really in a quandary given their previous interest in S&N. One way or another the Company will prevail but will Nath be at the helm.....no.....

How long can Smith and Nephew stay independent at this MCap?? Never seen a more vulnerable FTSE 250+ share that's such a gem of a buy at this stage of the market cycle. Money should be pouring into healthcare and surgical companies and S&N is missing out as a result of a CEO who lacks sentiment, charisma and drive. Under a bigger umbrella and a BoD with the vision and resources to crystallize value here, S&N is worth a lot more than this. Let's see who steps up to the plate.....US, Middle or Far East??

Why oh why did the BoD pick Nath.??? His decision to sell shares within 30 days of his appointment has poisoned investor sentiment. To take a company like S&N from £13.25 To £10.50 in less than 5 months is an epic CEO failure. The company is sound, has impeccable provenance and trust from consultants and medical staff worldwide, and is in a high barrier to entry sector. The backlog of operations requiring S&N products is burgeoning. The lack of enthusiastic positivity in the face of adversity by Nath was tangible. Absolutely useless when a new CEO can't motivate everyone with his infectious enthusiasm....not. If there was ever a time for an opportunistic bid it is NOW. Cable rate favourable and tax breaks huge for US predator but I wouldn't rule out a bid from the Middle or Far East as the new Malaysian facility is up and running. Time for a fresh start with new CEO and dynamic board reshuffle or t/o. Period. Excellent British Company with a Muppet at the helm. Change urgently needed for charisma injection.

Agreed...

Good price to upload. Analyst session should bounce. Bidders will circle below £12 as H2 is stronger and elective increases.

Not the most inspiring update from a CEO but not unexpected. H2 or bid should repair.

Decent operation in a stable country with resource drilling in prospects showing previous high ore grades. Pure punt on drill results and contiguous ore bodies. Not for widows and orphans but fun.....high risk, decent reward.

Having learned a salutatory lesson of management incompetence with Unbound UBG, I realise that ZYT will be the far better recipient of funds. Thankfully, I was very reserved in my exposure there and can now plump my 'on hold balance and proceeds from the sale (sold at a loss) here. With NAV greater than MCap, cash and having bought back it's own shares I'm much happier here. We all make a sh*t decision on occasions but hopefully gains cover the duds.

The directors here should resign. I've sold out my small holding as the jury was out pending positive news. Dreadful that they gave a positive update on progress less than a month ago and missed a huge hole in their projection forecast. Incompetent is too kind a word....pitiful is more befitting. Hotter......not. Interesting that they've managed to really p*ss off the demographic group they were chasing as a lot of them were shareholders. Talk about a footwear company shooting itself in the foot.....

https://www.unboundgroup.co.uk/

https://unboundgroupplc.com/unbound-brands/

Forget Primark...Chase the spenders with assets
Unbound group :Current trading and prospects

The Directors are pleased with the progress that Hotter Shoes has made in the current financial year to date. Revenues in the four months to 31 May 2022 were £16.9 million, up 12.5 per cent. on the prior year period (£15.0 million), with gross margin also improving to 68.7 per cent. (2021: 66.7 per cent.).

If the company uses this money wisely as explained in the fundraising notes, it could rapidly expand its enviable database. Data and especially selective demographic data is extremely valuable and ultimately saleable. Looks very interesting if correctly addressed.